Navigation Links
The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services
Date:1/14/2014

Toronto, Canada (PRWEB) January 14, 2014

In recent years, growing suspicion about the pharmaceutical industry and its motives and methods in product development and promotion has led to unprecedented levels of public mistrust of the industry. This mistrust, fueled by concerns about the insidious impact of commercialization of research, has been further fed by reports of spectacular fines to the world’s biggest pharmas for illegal marketing activities, allegations of industry suppression of negative clinical trial results, and fears of “influence peddling” through physician payments of various sorts.

The Physician Payments Sunshine Act (“The Sunshine Act”) is the US Congress’s response to these concerns. The Physician Payments Sunshine Act (Sunshine Act) requires manufacturers of drugs, medical devices and biologicals that participate in U.S. federal health care programs to report certain payments and items of value given to physicians and teaching hospitals.

Manufacturers are required to collect and track payment, transfer and ownership information beginning Aug. 1, 2013. Manufacturers will submit the reports to the Centers for Medicare & Medicaid Services (CMS) on an annual basis. In addition, manufacturers and group purchasing organizations (GPOs) must report certain ownership interests held by physicians and their immediate family members. The majority of the information contained in the reports will be available on a public, searchable website.

These new reporting requirements have imposed a considerable burden on all concerned, including IRBs, sponsors, CROs, clinical investigators, and certainly government. Will this added regulatory burden prove effective in promoting more ethical research with improved outcomes for patients and society?

For more information about this event or to register, visit

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Clinverse, Inc. Introduces ClinSpend to Meet Challenges of Sunshine Act Reporting Requirements
2. Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks
3. Online Courses Address Latest Healthcare Compliance Regulations
4. CfPIE Announces Advisory Board to Support Continued Life Sciences Training Alignment with Industry Regulations
5. Study dusts sugar coating off little-known regulation in cells
6. Swiss, EMA, US Pharmacopoeia and World Health Organization Authorities to Provide an Update on Cool Chain Regulations
7. Gordon Hunter's New Science Book Perfect for the Everyday Environmentalist
8. Bayer CropScience Reveals Insights into U.S. Potato Industry’s Top Needs for 2014 During Potato Expo
9. Isolation Sciences’ CAP Device Found to Reduce Energy Use by More Than 80 Percent
10. Fibrocell Science and Intrexon Expand Collaboration to Include Hypermobility-Type Ehlers-Danlos Syndrome
11. Science Magazine: Cancer Immunotherapy is the Medical Breakthrough of 2013; The CBCD Highlights the Link between Immunotherapy and Microcompetition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... GERMANTOWN, Md. and SUMMERLAND, British ... Corporation (NYSE: XON ), a leader ... an agreement to acquire  Okanagan Specialty Fruits (OSF), ... apple , the world,s first non-browning apple. Through ... trees yielding fruit that is more appetizing and convenient ...
(Date:2/27/2015)... Md. (PRWEB) February 27, 2015 ... Chromatography system (Nexera UC) can sequentially analyze up ... separation combined with high-sensitivity detection of targets by ... is designed to fulfill the measurement requirements of ... in food products, drug delivery and search for ...
(Date:2/27/2015)... -- Steep Hill, the industry leader in cannabis testing and ... a full service medical cannabis quality assurance laboratory in ... scientific tools and methodology to the state, for regulatory ... the only laboratory licensed by the New Mexico Department ... order to meet the recently adopted regulatory requirements pertaining ...
(Date:2/26/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... that develops and commercializes proprietary technologies and products for ... results for the fiscal first quarter ended December  31, ... Canadian dollars (CAD), unless otherwise stated. ... business from our existing customers and add to our ...
Breaking Biology Technology:Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... Avantium announced today the,successful completion of ... Avantium,is active in the development and commercialization ... and the improvement of,pharmaceutical products. The financing ... development programs. The focus of the next-generation ...
... and DUBLIN, Ireland, Oct. 29 ,Shire plc (LSE: SHP, Nasdaq: SHPGY) ... September 30, 2008., Q3 2008 Financial Highlights, - ... excluding ADDERALL XR(R) up 51% to $444 million - New ... 22%) - Total revenues up 28% to $779 million ...
... Oct. 29 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), ... that it,is scheduled to present at two upcoming ... in New York City and the,Credit Suisse Asian ... Wu, Senior Financial Manager, is scheduled to present ...
Cached Biology Technology:Avantium Completes EUR 18 Million Financing Round 2Avantium Completes EUR 18 Million Financing Round 3Avantium Completes EUR 18 Million Financing Round 4Shire's New Product Portfolio Delivers Strong Quarterly Performance 2Shire's New Product Portfolio Delivers Strong Quarterly Performance 3Shire's New Product Portfolio Delivers Strong Quarterly Performance 4Shire's New Product Portfolio Delivers Strong Quarterly Performance 5Shire's New Product Portfolio Delivers Strong Quarterly Performance 6Shire's New Product Portfolio Delivers Strong Quarterly Performance 7Shire's New Product Portfolio Delivers Strong Quarterly Performance 8Shire's New Product Portfolio Delivers Strong Quarterly Performance 9Shire's New Product Portfolio Delivers Strong Quarterly Performance 10Shire's New Product Portfolio Delivers Strong Quarterly Performance 11Shire's New Product Portfolio Delivers Strong Quarterly Performance 12Shire's New Product Portfolio Delivers Strong Quarterly Performance 13Shire's New Product Portfolio Delivers Strong Quarterly Performance 14Shire's New Product Portfolio Delivers Strong Quarterly Performance 15Shire's New Product Portfolio Delivers Strong Quarterly Performance 16Shire's New Product Portfolio Delivers Strong Quarterly Performance 17Shire's New Product Portfolio Delivers Strong Quarterly Performance 18Shire's New Product Portfolio Delivers Strong Quarterly Performance 19Shire's New Product Portfolio Delivers Strong Quarterly Performance 20Shire's New Product Portfolio Delivers Strong Quarterly Performance 21Shire's New Product Portfolio Delivers Strong Quarterly Performance 22Shire's New Product Portfolio Delivers Strong Quarterly Performance 23Shire's New Product Portfolio Delivers Strong Quarterly Performance 24Shire's New Product Portfolio Delivers Strong Quarterly Performance 25Shire's New Product Portfolio Delivers Strong Quarterly Performance 26Shire's New Product Portfolio Delivers Strong Quarterly Performance 27Shire's New Product Portfolio Delivers Strong Quarterly Performance 28Shire's New Product Portfolio Delivers Strong Quarterly Performance 29Shire's New Product Portfolio Delivers Strong Quarterly Performance 30Shire's New Product Portfolio Delivers Strong Quarterly Performance 31Shire's New Product Portfolio Delivers Strong Quarterly Performance 32Shire's New Product Portfolio Delivers Strong Quarterly Performance 33
(Date:2/13/2015)... 13, 2015 ACT Genomics Co., Ltd., ... to transform cancer genomic information into precision diagnosis ... has raised US$ 8 million in the its first ... Taipei, Taiwan , ACT Genomics has ... the aim to implement next generation sequencing (NGS) ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
(Date:2/5/2015)... Epic Sciences , a precision diagnostics company dedicated to improving ... , Ph.D., president and CEO, is scheduled to present at ... Valley, which is taking place at the Computer History Museum ... 26-28, 2015. Dr. Prahalad will give a ... Epic Sciences was a finalist in the PMWC,s Most Promising ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... can lower the risk of cardiovascular morbidities. This is the ... current issue of Deutsches rzteblatt International (Dtsch Arztebl ... chloride is in excess of 6 g per day increase ... notable in view of the fact that in the Western ...
... like HIV, reproduces and assembles new viruses is different than ... Understanding the steps a virus takes for assembly could allow ... diseases. The team studied a chicken virus called Rous ... to HIV. "The question is, how do retroviruses build ...
... long-term need for anticoagulant drug therapies may soon find help ... commonly known by the trade-name Plavix. Researchers in the ... clopidogrel may be a safe and effective treatment for dogs ... offer a safe alternative to NSAIDs for treating dogs at ...
Cached Biology News:Retrovirus replication process different than thought 2Plavix may be treatment for dogs at risk of thromboembolic disease 2
lid holder -see Blotters (Semi-Dry) for more info...
... the consumable measurement plate for ... individually controlled measurement sites. Each ... liquid flow channel system that ... solution and compound applications necessary ...
This kit is designed to select cells labeled with phycoerythrin- (PE-) conjugated antibodies. Kit includes reagents for labeling 3 x 10 9 cells and EasySep magnet....
... solutions to meet your laboratory's requirements for data management and quality control. ... ... ... CLARA® is the standard software for Staccato Systems and custom Allegro Modules allowing for the simple ...
Biology Products: